Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

"These mechanisms collectively may reduce the risk of cognitive decline, particularly in diabetic patients, and warrant ...

A study reveals SGLT-2 inhibitors significantly reduce dementia risk in type 2 diabetes patients, with effects strengthening ...

By inhibiting SGLT-2 protein, these drugs enhance glucose excretion in urine, reducing blood glucose levels. This mechanism ...

The findings support the hypothesis that SGLT-2 inhibitors might influence dementia risk through mechanisms beyond glucose control, possibly involving direct neuroprotective effects or improved ...

The use of SGLT2 inhibitors was associated with a lower risk for recurrent ischemic stroke and all-cause mortality among patients with type 2 diabetes. The use of sodium-glucose co-transporter-2 ...

In ACTIV-4a, 215 (75%) of 285 patients in the SGLT2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) plus standard-of-care group did not require respiratory or cardiovascular organ support ...

SGLT2 inhibitors and mitochondrial antioxidants reversed this effect. While the study is incomplete and preliminary, its strength lies in introducing hiPSC-CMs as a tool for investigating HFpEF ...